Inactive Instrument

EnzymeBioSystems

Biotechnology & Medical Research

EnzymeBioSystems announced that it has received $0.779526 million in funding

October 23, 2017

On October 24, 2017, EnzymeBioSystems (OTCPK:ENZB) closed the transaction. The company raised $779,526 in the transaction from 15 investors.

Latest news about EnzymeBioSystems

EnzymeBioSystems Announces Management Changes	18-01-04	CI
EnzymeBioSystems Announces Change of its Corporate Headquarters	17-12-14	CI
EnzymeBioSystems announced that it has received $0.779526 million in funding	17-10-23	CI
EnzymeBioSystems announced a financing transaction	17-09-05	CI
The Board of EnzymeBioSystems announced the spin-off of Shareholder Acquisition Corp.	17-01-11	CI
EnzymeBioSystems Auditor Raises 'Going Concern' Doubt	15-11-11	CI
Enzymebiosystems Announces Change of its Principal Executive Offices	15-10-14	CI
EnzymeBioSystems will Change its Ticker to ENZBE from ENZB	15-10-02	CI
EnzymeBioSystems Announces Executive Changes	15-09-25	CI
EnzymeBioSystems Provides Product Development Update	15-08-20	CI
EnzymeBioSystems will Change its Ticker to ENZB from ENZB.D	15-07-16	CI
EnzymeBioSystems will Change its Ticker to ENZBD from ENZB	15-06-18	CI
EnzymeBioSystems Announces Preclinical Xenograft Studies Show Positive Results for Amooranin	14-12-10	CI
EnzymeBioSystems Announces Management Changes	14-10-23	CI
EnzymeBioSystems Changes its Principal Executive Office	14-10-23	CI
EnzymeBioSystems Appoints Gary Rojewski as CEO, Effective June 2, 2014	14-05-23	CI

EnzymeBioSystems is a development-stage company. The Company researches specialty enzymes and enzyme related products. The Company utilizes enzyme technologies to develop commercial solutions for a range of applications within the specialty chemical industry. It seeks to develop specialty enzymes to eliminate the side effects and toxicity of the new commercially developed products. The Company's product candidate, Amooranin, is indicated for the treatment of multiple breast cancer. Amooranin is a triterpene acid with a structure isolated from the stem bark of Amoora rohituka, a tropical tree in India. The Company intends to research the study of the use of Amooranin. Specifically, the two areas of this study includes an exam of the in vitro cytotoxicity of Amooranin against hepatocellular carcinoma cells, and investigate the dose responsive antitumor actions of Amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research